

Healthcare Resource Utilization and Economic Burden of Multiple Sclerosis in Chinese Patients: Results from a Real-World Survey

Jia Y^{1†}, Sun C^{1†}, Li H¹, Qiao X¹, Tang M², Geng M², Jones E³, Pike J⁴, Unsworth M³, Hu M¹

¹Fudan University School of Public Health, Department of Health Economics, Shanghai, China

²Novartis Pharma AG, HEOR & Access Strategy, Value Access, Beijing, China

³Adelphi Real World, Central Nervous System, Bollington, UK

⁴Adelphi Real World, Statistics and Data Analytics, Bollington, UK

[†]Yusheng Jia and Chenhan Sun contributed equally to this work and share first authorship.

Corresponding author: Dr Min Hu; Email: humin@fudan.edu.cn; Affiliation: Fudan University School of Public Health, Department of Health Economics, Shanghai, China

SUPPLEMENTAL MATERIAL

Appendix. Disease modifying treatments licensed for MS in China

Date of market authorization	Aubagio (teriflunomide)	Gilenya (fingolimod)	Mayzent (siponimod)	Tecfidera (dimethyl fumarate)	Kesimpta (ofatumumab)
Launch	2017	2019	2020	2021	2021
NRDL Reimbursement	2019	2020	2020	2022	2022

NRDL, National Reimbursement Drug List